- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
VPHM Market Currents
more »
-
May 1 Weaker-than-expected Q1 results weigh on shares of ViroPharma (VPHM -9.5%), which has already dropped nearly 30% in the past month as what has been the drug devloper’s biggest seller, Vancocin, faces potential generic competition. Citing the generic threat, VPHM cuts its 2012 revenue target by nearly 25%.
Comment![Healthcare, On the Move]
VPHM Related Articles
more »
VPHM News
more »
-
at MarketWatch.com (May 1, 2012)
-
at MarketWatch.com (May 1, 2012)
-
at CNBC.com (Mar 6, 2012)
-
at MarketWatch.com (Jan 17, 2012)
-
at MarketWatch.com (Oct 27, 2010)
VPHM Press Releases and Filings
more »
-
PR Newswire (Tue, 12:30PM)
-
PR Newswire (May 2, 2012)
-
PR Newswire (May 1, 2012)
-
PR Newswire (Apr 23, 2012)
-
PR Newswire (Apr 10, 2012)
VPHM Latest Transcript
more »
-
Wed, Oct 28, 2009Popular searches: viropharma, cinryze, patients, sales force, milano, pip, subcutaneous, vanco, acqui, Vancocin .
VPHM Cramer
more »
-
Tue, Aug 12, 2008
-
Wed, Oct 3, 2007
-
Wed, Apr 11, 2007
VPHM Instablog posts
more »
VPHM vs. ETF Alternatives
Company Description
ViroPharma Incorporated and subsidiaries is a global biotechnology company dedicated to the development and commercialization of products that address serious diseases, with a focus on products used by physician specialists or in hospital settings. We have two marketed products and two... More
